Wizard of Ops
  • Home
  • About
    • Newsletters
    • Volland
    • Private Volland Education
  • Resources
    • White Paper
    • FAQs
    • Articles
    • Webinars
  • Contact

Wizard of Ops Articles

February Fundamental Trades: Month-End Updates

2/28/2018

0 Comments

 
These updates will be available to subscribers only starting in April. 

In all cases, SLM, GM, CELG, and NBIX, we are holding our sold puts, even though all but NBIX are below their strike values.  We want to own these stocks, and we may by March expiration.  There was only one piece of fundamental news.

CELG received an refuse to file (RTF) from the FDA on their prized pipeline drug, ozanimod, designed to treat MS.  Dave stated that this will likely set the launch of this drug back approximately a year, but because the RTF wasn’t issued for a safety reason, it will not hurt chances for approval that much. 

That being said, my personal feelings are that this points to management issues. From a large biotech company, this is usually avoided by constant communication with the FDA and thorough disclosure in the filings. While the CELG fundamental case changes very little, I am put on alert, and I think management needs to prove themselves a little bit here.  I would still own CELG at these levels, but am put more on alert. 
0 Comments



Leave a Reply.

    The Wizard

    Jason DeLorenzo

    Archives

    November 2024
    September 2023
    May 2023
    April 2023
    January 2022
    October 2021
    March 2021
    January 2021
    October 2019
    August 2019
    January 2019
    December 2018
    November 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    March 2018
    February 2018
    January 2018

    Categories

    All

    RSS Feed

About
Form ADV
​
Business Continuity

FAQ
Terms of Use
Privacy Policy
© Copyright 2025.
All Rights Reserved.
  • Home
  • About
    • Newsletters
    • Volland
    • Private Volland Education
  • Resources
    • White Paper
    • FAQs
    • Articles
    • Webinars
  • Contact